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Effects of dietary supplementation of pioglitazone on metabolism, milk yield and 25 
reproductive performance in transition dairy cows 26 
Abstract 27 
The objective of this study was to investigate the effect of dietary supplementation of 28 
pioglitazone (PGT), a specific ligand for PPARγ, on metabolic dynamics, milk production, 29 
and reproductive performance of transition dairy cows. Eighty multiparous Holstein cows in 30 
their second or more lactations were blocked by the calving date and parity and assigned 31 
randomly to four dietary groups (n=20 cow/treatment) including control (no PGT-/-), 32 
supplemented with PGT (6 mg PGT/kg body weight) from day -14 to +21 relative to 33 
parturition (PGT+/+) or only during prepartum (PGT+/-) or postpartum periods (PGT-/+). 34 
Postpartum body condition score and body weight loss decreased (P < 0.05) in all PGT 35 
supplemented groups. Milk yield was not affected by PGT supplementation (P > 0.05). 36 
Percentage of milk fat decreased (P < 0.05) in all PGT-treated groups; however, milk fat 37 
yield was lower (P < 0.05) in PGT (+/+) and PGT (+/-) groups compared to PGT (-/-). 38 
Peripartum (d -7 to +7) concentrations of plasma non-esterified fatty acids (NEFA) and β-39 
hydroxybutyrate (BHBA) decreased in PGT (+/+) but not in the PGT (-/-) group (P < 0.05). 40 
During the postpartum period, PGT reduced (P > 0.05) plasma concentrations of NEFA in all 41 
PGT-treated groups but did not affect BHBA level. Plasma concentrations of triglycerides 42 
(TG) decreased in all PGT supplemented groups. Supplementation of PGT decreased the 43 
peripartum concentrations of plasma glucose in PGT cows. Plasma concentrations of IGF-I 44 
were higher in PGT (+/+) compared to the control group during both the peri- and postpartum 45 
periods. Plasma concentrations of growth hormone and insulin were not affected by PGT 46 
treatment (P > 0.05). Mean days to ovulation were lower and the proportion of cows 47 
ovulating by d 14 postpartum was higher in PGT (+/+) and PGT (+/-) compared to control. 48 
Days open were shorter in PGT (+/+), PGT (+/-) and PGT (-/+) groups compared to control. 49 
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The proportion of pregnant cows at 120 DIM was higher in PGT (+/+) and PGT (+/-) 50 
compared to the control. The results showed positive effects of dietary supplementation of 51 
PGT, especially supplementation during both the pre- and postpartum periods, on metabolic 52 
dynamics, ovarian function and reproductive performance in transition dairy cows. 53 
Keywords: Insulin resistance; pioglitazone; metabolic dynamics; milk yield; reproductive 54 
performance; dairy cows. 55 
1. Introduction 56 
The transition period is a crucial period in dairy cows, affecting their postpartum health, 57 
reproduction and milk performance, and is accompanied by homeorhetic adaptations in 58 
glucose and lipid metabolism [1, 2]. The increased overall energy demand in transition cows 59 
is supported by a simultaneous decrease in glucose oxidation by peripheral tissues [2], an 60 
increase in glucose output by the liver [3], and also by stimulation of body fat mobilization, 61 
that is facilitated through a decrease in the response of adipose tissue to insulin [4], known as 62 
insulin resistance. 63 
Insulin resistance during the prepartum period is a part of the homeorhetic mechanisms that 64 
develop in peripheral tissues, and continues into early lactation to direct the nutrients toward 65 
the fetus and mammary glands [1]. Decreased sensitivity of peripheral tissues to insulin 66 
facilitates mobilization of non-esterified fatty acids (NEFA) to compensate and mitigate the 67 
period of negative energy balance (NEB); however, it may be followed by a rapid decrease in 68 
dry matter intake and a high spike of NEFA during the transition period [5, 6]. High 69 
concentrations of NEFA in transition cows contribute to energy and immune related 70 
metabolic disorders, such as displaced abomasum, ketosis, fatty liver, metritis and mastitis 71 
[7], and result in a greater risk of insulin resistance [8]. 72 
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The potential for modulation of adipose tissue metabolism may suggest ways to moderate the 73 
acute spike in circulating NEFA concentrations. In this regard, several strategies have been 74 
tried to decrease insulin resistance and attenuate metabolic disorders [9-13]. A 75 
pharmacological method, based on administration of an exogenous ligand of peroxisome 76 
proliferator and activator receptors (PPARs), has been proposed as a newer approach for 77 
controlling the prepartum insulin resistance in dairy cows [14-16]. 78 
The PPARs which are widely distributed in the body, especially in the bovine adipose tissue 79 
as well as the reproductive organs [17] and mammary glands [18-20], have tremendous 80 
effects on body fat metabolism as a differentiation regulator of adipocytes [21]. Activation of 81 
these receptors in adipose tissues, influence adipocytes capacity for fatty acid storage and 82 
regulate several adipokines affecting insulin resistance [22]. PPARγ, the most prevalent 83 
PPAR in the adipose tissues, is activated by several endogenous [21, 22] and exogenous 84 
ligands such as thiazolidinediones (TZDs).  85 
There is evidence that TZDS injection was able to reverse the TNFα-induced insulin 86 
resistance in steers [23], and improve energy efficiency in beef cattle [24]. It was also shown 87 
that administration of TZDs during late pregnancy in dairy cows maintained higher 88 
postpartum BCS, decreased plasma concentrations of NEFA and liver TG accumulation, 89 
increased peripartum DMI and plasma glucose levels, and stimulated postpartum ovarian 90 
activity [15, 16, 25]. Accordingly, dietary supplementation of about 0.114 mg TZDs per kg 91 
BW in beef cattle also improved energy efficiency, and liver and muscle fatty acid oxidation 92 
[24]. These findings demonstrate the effectiveness of TZDs on attenuating insulin resistance 93 
and improving metabolic dynamics of transition dairy cows. 94 
Pioglitazone, as a TZD drug, is a synthetic and specific ligand for PPARγ that is used for 95 
treatment of type 2 diabetes mellitus in human [26]. By binding and activating PPARγ, 96 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
pioglitazone affects plasma lipids, adipose tissue, and liver to reduce insulin resistance [26, 97 
27]. The bioavailability of PGT after oral administration was 62% in sheep [28], 83% in 98 
humans [29], and 50% in rats [30]. In dairy cows, the bioavailability and half-life of PGT 99 
following oral administration was about 60%, showing acceptable potential of PGT for 100 
dietary supplementation [31]. Although, there are several studies on dietary supplementation 101 
of TZDs in beef cattle [23, 24] and dairy cows [15, 16, 25], the use of this drug has not been 102 
approved yet, and further investigations are needed to reveal the effects of TZDs on animal 103 
metabolism and health. To our knowledge, there are no reports on the effect of dietary 104 
supplementation of TZDs on metabolism in transition dairy cows or postpartum reproduction. 105 
The objectives of this experiment were to determine the effect of dietary supplementation of 106 
pioglitazone hydrochloride during the transition period on metabolism, milk production and 107 
reproductive performance in dairy cows. 108 
2. Materials and methods 109 
2.1. Experimental design 110 
The experiment was conducted on high-producing Holstein dairy cows (42 kg/day) in a 111 
commercial dairy farm in the north of Iran from February to April 2012. Eighty multiparous 112 
cows (parity 2-6) with no overt clinical disease history were blocked by calving date and 113 
parity, and allocated in four dietary groups (n=20 cow/treatment). PGT was obtained as 114 
pioglitazone hydrochloride from Hetero Drugs (India; Batch No: PHD 0510001) and kindly 115 
provided by Darou Pakhsh Co., Tehran, Iran. Considering about 60% bioavailability for oral 116 
administration of pioglitazone in ruminants [28, 31] and also previous studies [15, 16, 25] 117 
reporting that intravenous administration of 2 or 4 mg TZD/kg BW effectively influenced 118 
metabolism and performance of transition cows, a dose of 6 mg PGT/kg BW was used in the 119 
present experiment. Experimental period was 35 d, starting on d 14 before expected 120 
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parturition to d 21 postpartum. Diets consisted of PGT (+/+): supplementation of PGT during 121 
the pre and postpartum period (d −14 to +21 relative to parturition), PGT (+/-): 122 
supplementation of PGT only during the prepartum period (d −14 to parturition), PGT (-/+): 123 
supplementation of PGT only during the postpartum period (parturition to d +21 relative to 124 
parturition) and PGT (-/-): no PGT supplementation (control), (Figure 1). Cows were fed ad 125 
libitum, a common total mixed ration (TMR) during the pre- and postpartum periods twice 126 
per day (0800 and 1600 hours), supplemented with or without PGT.  127 
Diets were formulated (Table 1) according to the requirements during the pre and postpartum 128 
as suggested by NRC [32]. Cow assignment to treatments was balanced for calculated 129 
previous 305-d mature-equivalent milk yield and BCS. The average (±SE) of parity in PGT 130 
(+/+), PGT (+/-), PGT (-/+), and PGT (-/-) groups was 2.80±0.25, 3.10±0.30, 3.30±0.33, and 131 
2.70±0.24, respectively.  132 
The diets were sampled weekly, and analyzed for crude protein (CP, method 988.05; AOAC, 133 
1990); ether extract (method 920.39; AOAC, 1990), acid detergent fiber (method 973.18; 134 
AOAC, 1990) and neutral detergent fiber [33]. At weekly intervals, body weight and BCS 135 
were measured. BCS was evaluated using a 5-scale system by three experts and the average 136 
of which was taken as the BCS for each cow [34]. 137 
2.2. Milk and blood sampling 138 
After parturition, cows were milked 3 times per day, at 07.00, 14.00, and 23.00 hours, and 139 
milk yield of individual cows was recorded at each milking, until d 30 postpartum. Milk 140 
samples were collected weekly from all 3 consecutive milking in plastic vials, preserved with 141 
potassium dichromate, and stored at 4°C. Milk samples were analyzed for fat, protein, 142 
lactose, and total solids using MilkoScan (134 BN Foss Electric, Hillerød, Denmark). Milk 143 
composition were calculated based on the product of the milk production yield and milk 144 
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composition at each milking on those days, as a weighted mean, and used for statistical 145 
analysis. 146 
Blood samples were collected from 10 cows in each treatment, on d -14, -7, 0, 7, 14, and +21 147 
(d 0 = parturition). Blood was collected via the coccygeal vein in evacuated glass tubes 148 
containing EDTA (10.5 mg, Monoject; Sherwood Medical, St. Louis, MO, USA). Within 1 h 149 
following sampling, plasma was harvested by centrifugation (3000 × g, 15 min at 4°C) and 150 
stored at −18°C until further analysis. Plasma concentrations of cholesterol, TG and glucose 151 
were measured using Pars Azmoon kits according to the manufacturer’s procedures (Pars 152 
Azmoon Co., Tehran, Iran). The inter- and intra-assay coefficients were 2.8 and 1.7% for 153 
cholesterol, 3.1 and 2.4% for TG and 4.5 and 3.1% for glucose assay. Plasma concentrations 154 
of NEFA and BHBA were measured using commercial kits (Randox Laboratories Ltd., 155 
London, UK) with a Technicon-RA 1000 Autoanalyzer (DRG Co., Marburg, Germany). The 156 
inter- and intra-assay coefficients of variations for NEFA and BHBA assays were 6.3, 4.2, 157 
4.6 and 3.8%, respectively. 158 
 Blood concentrations of insulin and progesterone (Diaplus Inc., USA), IGF-1 (Hangzhou 159 
Eastbiopharm Co., Ltd., USA) and GH (Monobind Inc Lake Forest, CA, USA) were 160 
measured with specific ELISA kits, following the manufacturer’s instructions. The inter- and 161 
intra-assay coefficients of variation were 7.2, 5.4% for insulin, 5.1, 3.2% for progesterone, 162 
6.9, 5.2% for IGF-1, 7.8 and 6.5% for GH assay. 163 
2.3. Reproductive management 164 
A PreSynch/Ovsynch program starting on d 30 postpartum was conducted [35]. Briefly, the 165 
PreSynch estrous cycle synchronization was carried out by 2 injections of PGF2α (500 µg, 166 
Cloprostenol Sodium, i.m.; Estroplan, Parnell technologies PTY. LTD., Alexandria, 167 
Australia) given 14 d apart. The Ovsynch program started 14 d after the second PGF2α 168 
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injection. In the Ovsynch program, cows were injected an intramuscular GnRH (100 µg 169 
gonadorellin acetate, Gonabreed, Parnell Technologies PTY. LTD., Alexandria, Australia), 170 
followed by PGF2α injection 7 d later. An additional GnRH was injected 48 h after PGF2α 171 
injection. Cows were inseminated artificially 16 h after GnRH injection.  172 
Cows were inseminated and excluded from the program if they showed estrus signs following 173 
the second injection of PGF2α in presynchronization phase (d 44 postpartum) until the end of 174 
the reproductive program. Estrus was detected using a combination of behavioral 175 
observations (two times daily) and pedometer activity. One technician inseminated all cows 176 
until the end of the experiment. The reproductive traits including postpartum ovulation, 177 
conception rate, pregnancy per AI, service per conception, days open, days to first service 178 
and days to first estrus were recorded during the experiment.  179 
Number of days to first ovulation was determined using both ultrasonography and 180 
progesterone assay (3 times per week). Ovarian follicular activity was monitored by 181 
transrectal ultrasonography using a real-time linear scanning ultrasound diagnostic system (B 182 
mode; Piemedical, Falco 100; 8 MHz transducer), 2 times per week, beginning on d 8 183 
postpartum and continuing through d 28 postpartum. Ovulation was considered to have 184 
occurred 3 d before plasma progesterone was greater than or equal to 1 ng/mL [25]. 185 
2.4. Statistical analysis 186 
Data measured over time (BCS, BW, milk yield and composition, blood hormones and 187 
metabolites), were analyzed by the MIXED procedure (SAS Institute Inc., Cary, NC), for 188 
peripartum (d −7 to +7) and postpartum (d 0 to +21), separately. The model included the 189 
fixed effects of treatment, time, the interaction between treatment and time, and the random 190 
effect of cows nested within treatments. Pretreatment values for plasma variables BW, and 191 
BCS measured or assessed at the beginning of the experiment, were used as covariates to 192 
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their corresponding measurements during the treatment period; however, covariates were 193 
removed from the model if P > 0.20, and the data reanalyzed. Mathematical model and its 194 
components were: 195 
 196 
where yijk is observation on cow k at the sampling time j given treatment i; µ is the overall 197 
mean; Ti is fixed effect of treatment; tj is fixed effect of sampling time j (weeks); (T×t)ij is the 198 
two-way interaction of treatment i by sampling time j; δ(T)il is the random effect of cow k 199 
nested within treatment i, and eijkl is residual random error.  200 
Time of sampling (weeks) was used in the REPEATED statement and the tukey test was used 201 
for multiple comparison tests. Results were expressed as least squares means and SEM. 202 
Before analysis of the reproductive data, 6 cows were removed from the data set (1, 1, 2 and 203 
2 cows from PGT +/+, PGT +/-, PGT -/+ and PGT -/-, respectively). These cows were culled 204 
after d 50 postpartum because of physical injury or reproductive problems. The interval 205 
between calving and day of the first ovulation, days to first estrus, days to first service, 206 
interval between inseminations, and days open were analyzed using survival analysis and the 207 
product limit method of the Kaplan–Meier model using the LIFETEST procedure of the SAS. 208 
Number of services per conception was analyzed by the GENMOD procedure using a 209 
Poisson distribution. Binomially distributed data such as conception and ovulation rate were 210 
analyzed by the GENMOD procedure using a binary distribution and a logit odds ratio link. 211 
Statistical significance and tendencies were declared at P < 0.05 and 0.05 ≤ P ≤ 0.10, 212 
respectively. 213 
 214 
 215 
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3. Results 216 
3.1. Plasma metabolites 217 
The overall plasma concentrations of plasma NEFA, BHBA, cholesterol, triglyceride and 218 
glucose during the peripartum (d −7 to +7 relative to parturition) and postpartum (parturition 219 
to d 21 postpartum) periods are presented in Table 2. Plasma NEFA concentrations decreased 220 
in PGT (+/+) compared to PGT (-/+) and PGT (-/-) groups during the peripartum period (P < 221 
0.05); however, during the postpartum period, plasma NEFA concentrations decreased (P < 222 
0.05) in PGT (+/+), PGT (+/-) and PGT (-/+) compared to PGT (-/-). The effect of PGT 223 
supplementation on plasma BHBA concentrations was not significant during the postpartum 224 
periods (P > 0.05); however, PGT supplementation decreased plasma BHBA concentrations 225 
in PGT (+/+) and PGT (+/-) compared to the control group during the peripartum period (P < 226 
0.1 and P < 0.05, respectively). Plasma concentrations of TG were decreased (P < 0.05) in 227 
PGT (+/+), PGT (+/-) and PGT (-/+) compared to PGT (-/-) during both the peri- and 228 
postpartum periods (Table 2). Concentration of plasma glucose was not affected by the diets 229 
during the postpartum period, while PGT supplementation increased (P > 0.05) plasma 230 
concentrations of glucose in PGT (+/+) and PGT (+/-) compared to PGT (-/-) during the 231 
peripartum period (Table 2). 232 
3.2. Plasma hormones 233 
The overall plasma concentrations of plasma insulin, GH and IGF-1 during the peri- and 234 
postpartum periods are presented in Table 3. Plasma insulin and GH concentrations were not 235 
affected (P > 0.05) by treatment during the peri- or postpartum periods (Table 3). Plasma 236 
concentration of IGF-1 increased (P < 0.05) in PGT (+/+) compared to PGT (-/-) during the 237 
peri- and postpartum periods. However, during the postpartum period, plasma concentration 238 
of IGF-1 tended (P < 0.1) to be higher in PGT (+/+) than PGT (-/+) group (Table 3).  239 
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3.3. Productive traits 240 
The overall effects of PGT supplementation on BW, BCS and milk yield and milk 241 
composition are shown in Table 4. There was no significant effect of PGT supplementation 242 
on BW and BCS; however, PGT supplementation decreased (P < 0.05) BW loss in PGT (+/+) 243 
and PGT (+/-) compared to PGT (-/-), and BCS loss in PGT (+/+), PGT (+/-) and PGT (-/+) 244 
compared to PGT (-/-) (P < 0.05, table 4). 245 
Supplementation of PGT did not affect milk yield and 4% fat-corrected milk yield during the 246 
first 30 d postpartum (Table 4). The percentage of milk fat was decreased by PGT 247 
supplementation in PGT (+/+), PGT (+/-) and PGT (-/+) compared to PGT (-/-); however, 248 
daily milk fat production (kg) decreased in PGT (+/+) and PGT (+/-) and tended to be 249 
decreased (P < 0.10) in PGT (-/+) compared to PGT (-/-). Supplementation of PGT did not 250 
affect other milk constituents (Table 4). 251 
3.4. Reproductive traits 252 
The effects of PGT supplementation on reproductive traits are shown in Table 5. The 253 
proportion of cows ovulating by 14 d postpartum was higher in PGT (+/+) and PGT (+/-) 254 
than the PGT (-/-) group (P < 0.05). The proportion of cows ovulating by 21 d postpartum 255 
tended to be higher in PGT (-/+) compared to PGT (-/-) cows. Mean days to first ovulation 256 
was lower in PGT (+/+) and PGT (-/+) groups compared to PGT (-/-). The mean days open 257 
was decreased in cows fed with PGT diets compared to control cows. The number of days to 258 
first estrus was not affected by PGT supplementation; however, days to first service was 259 
decreased in PGT (+/+) and PGT (-/+) compared to PGT (-/-) cows (P < 0.05; table 5). The 260 
interval between the first and second inseminations was shorter in PGT (+/+) and PGT (+/-) 261 
than that in PGT (-/-) cows (P < 0.05). The number of service per conception was lower in 262 
PGT (+/+) and PGT (+/-) compared to PGT (-/-) cows (P < 0.05). Conception rate at first 263 
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service tended to be higher in PGT (+/-) than in the PGT (-/-) group (P < 0.10). The 264 
proportion of pregnant cows by 120 DIM was higher in PGT (+/+), PGT (+/-) and PGT (-/+) 265 
compared to PGT (-/-) cows (P < 0.05). 266 
4. Discussion 267 
Insulin resistance in peripheral tissues during the prepartum period and early lactation in 268 
dairy cows directs nutrients toward the uterus and mammary glands in support of the fetus 269 
and lactation [1]. However, in pre- and postpartum cows, insulin resistance is probably 270 
followed by an increase in circulating concentrations of NEFA, and the decrease in dry 271 
matter intake leads to several postpartal metabolic disorders and poor reproductive 272 
performance [5, 6]. 273 
Prepartal administration of TZD was beneficial in controlling the circulating NEFA level, 274 
improving DMI and attenuating the insulin resistance [15, 16, 25]. We expected that dietary 275 
supplementation of PGT, as a specific ligand of PPAR-γ, would improve energy and fat 276 
metabolism and consequently improve reproductive performance in transition dairy cows. 277 
Although, there are several studies on the use of these TZDs in dairy and beef cattle [15, 16, 278 
24, 25, 31], it has not been approved and further investigations are required; however, the 279 
present study is the first study to investigate the effect of dietary TZDs on the metabolism and 280 
reproductive performance in transition dairy cows. 281 
Plasma NEFA concentrations decreased in cows receiving PGT during the pre- and 282 
postpartum periods; however, in the peripartal period, NEFA was decreased when cows 283 
received PGT during both pre- and postpartum periods. In agreement with these results, 284 
Smith et al. [15] showed that administration of TZD decreased plasma NEFA concentrations 285 
during the prepartal period and tended to decrease peripartal NEFA concentration. Ghoreishi 286 
[36] showed that dietary supplementation of 4.0 mg PGT/kg BW during the transition period 287 
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decreased plasma peripartal concentrations of NEFA. It was also reported that administration 288 
of 2.0 mg TZD/kg BW to steers was effective in alleviating insulin resistance, induced by 289 
administered TNF-α, and reducing the increased plasma NEFA after d 2 of treatment [23].  290 
These results are explained by the possible effect of TZDs on increasing DMI during the 291 
peripartal and postpartal periods [15, 25, 36], and/or by direct effect of TZDs on re-292 
esterification of fatty acids and induction of phosphoenol pyruvate carboxykinase in adipose 293 
tissue, that increases glyceroneogenesis and promotes a futile cycle [37]. Probably, the 294 
glyceroneogenesis-dependent fatty acid-lowering effect of TZDs could be an essential aspect 295 
of the antidiabetic action of these compounds. Generally, lower levels of plasma NEFA 296 
showed that PGT may decrease fat mobilization or increase free fatty acid re-esterification or 297 
stimulate hepatic capacity for oxidation of NEFA.  298 
The lower plasma concentrations of BHBA during the peripartal period in cows treated with 299 
PGT was in agreement with the results of Smith et al. [15], who reported a decrease in 300 
plasma BHBA concentration by administering 2.0 mg TZD/ kg BW. However, Smith et al. 301 
[25] reported an increase in peripartal BHBA concentration by TZD administration, and 302 
Ghoreishi [36] found no significant effect of dietary supplementation of 4.0 mg PGT on 303 
plasma BHBA concentration. The lower plasma concentrations of BHBA may be a result of 304 
lower plasma NEFA availability in PGT-treated cows (Table 2) and increased hepatic 305 
capacity to oxidize palmitic and stearic acids [38] which lowers plasma BHBA. However, 306 
because dietary or pharmacologic manipulation of hepatic PPARs in dairy cows would 307 
increase β-oxidation of fatty acids and likely increase plasma BHBA [39], it is probable that 308 
lower BHBA levels in this experiment are caused by an indirect effect of PGT on the liver, by 309 
lowering the plasma NEFA, or by increasing DMI. 310 
The effectiveness of PGT on fat metabolism was also approved where plasma concentration 311 
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of TG decreased in PGT-treated cows during both the peri- and postpartal periods. Ghorieshi 312 
et al [36] reported no effect of dietary supplementation of 4.0 mg PGT per kg BW on plasma 313 
TG in transition cows; however, consistent with the results of the present study, calves from 314 
cows treated with PGT had lower plasma TG concentration. According to results of Palmer et 315 
al [40], PGT may decrease expression of MTTP (microsomal triglyceride transfer protein) 316 
and consequently decreases incorporation of TG in VLDL and plasma concentration of TG. 317 
In addition, limited mobilization of body fat as a result of PGT treatment may reduce 318 
precursors required for TG synthesis in the liver. Generally, the approved beneficial effects of 319 
TZDs on enhancing insulin sensitivity in cow’s peripheral tissues [15, 16, 23] is the most 320 
likely pathway by which PGT treatment decreased body fat mobilization in dairy cows, as 321 
previously documented for the human adipocytes [41]. 322 
In the present study, peripartum plasma concentrations of glucose increased in cows which 323 
received PGT for 14 d prepartum (PGT +/+ and PGT +/-). This finding supported the results 324 
of previous studies in which perpartal administration of 2.0 or 4.0 mg TZDs/ kg BW 325 
increased plasma concentrations of glucose during the peripartal period [16, 25]. However, 326 
the effect of TZDs on plasma glucose was not significant in other studies [15, 36]. It has been 327 
demonstrated that administration of TZDs increased DMI in transition dairy cows [15, 36] 328 
and laboratory animals [42, 43]. Therefore, the higher concentration of glucose during the 329 
peripartal period may be a direct effect of higher DMI in PGT- treated cows. Moreover, 330 
prepartal administration of TZDs decreased accumulation of TG in the liver of dairy cows 331 
[25] and humans [44, 45] and that would increase gluconeogenic capacity [46, 47] and 332 
plasma concentration of glucose.  333 
It has been suggested that TZDs may increase plasma concentration of insulin in dairy cows 334 
[15]; however, in agreement with results of Schoenberg and Overton [16], no significant 335 
change in plasma concentration of insulin was observed in the current study. A previous 336 
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study in animal models [21] showed that TZDs administration may improve pancreatic β-cell 337 
function and insulin production; however, Kushibiki et al. [23] reported a decrease in plasma 338 
concentrations of insulin in TZD-treated steers following improvement in glucose utilization. 339 
The differences between animals, dosage and/or type of administration might have resulted in 340 
inconsistent responses to this compound. On the other hand, we expected an increase in 341 
plasma insulin in those cows that had a higher plasma concentration of glucose. However, no 342 
increase in insulin levels may be due to an inadequate increase in plasma concentration of 343 
glucose or a failure of the liver to secrete insulin at a level appropriate for plasma glucose 344 
concentrations. 345 
 Plasma concentration of IGF-1 was significantly increased in PGT (+/+) and non-346 
significantly in PGT (+/-) and PGT (-/+) compared to PGT (-/-), but plasma concentrations of 347 
GH were not affected by PGT treatment. In peripartal dairy cows, concentrations of plasma 348 
IGF-1 are low but GH level is high [48]. It has been suggested that decreases in liver growth 349 
hormone receptor 1A (GHR 1A) before calving causes the uncoupling of the somatotropic 350 
axis in postpartal cows [48]. The subsequent recoupling of the somatotropic axis has been 351 
linked to postpartal nutrition and energy balance and is probably dependent on GHR 1A [49]. 352 
In response to insulin, GHR 1A and IGF-I expression increased in the liver of postpartal dairy 353 
cows [49], humans and other species [50]. In the present study, NEB indexes (NEFA and 354 
BHBA) decrease and plasma concentration of glucose increased in PGT-treated cows. These 355 
effects were also demonstrated by increased DMI and a decrease in the NEB during the 356 
postpartum in dairy cows that were subjected to TZDs [15, 25]. As an insulin sensitizing 357 
agent, PGT may also improve the responsiveness of the liver and other peripheral tissues to 358 
insulin. Therefore, there is a possibility that PGT increased the sensitivity of liver to insulin 359 
and caused greater expression of GHR 1A receptor and IGF-1 synthesis in the liver. 360 
In this experiment, milk yield was not affected by PGT, but milk fat percentage and yield 361 
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were decreased by d 30 postpartum. Smith et al. [25] showed that prepartal administration of 362 
4.0 mg TZDs/kg BW tended to decrease milk fat percentage by d 63 postpartum. Considering 363 
the fact that a part of plasma NEFA and blood fat metabolites incorporated directly into milk 364 
fat [48], the decrease in milk fat is explained by lower plasma NEFA and other fat 365 
metabolites in PGT-treated cows. Moreover, administration of endogenous or exogenous 366 
ligands of PPAR-γ to dairy sheep and goats regulated genes involved in triacylglycerol 367 
synthesis and secretion in mammary gland epithelial cells and milk fat content [18, 19]. TZDs 368 
also altered lipogenic gene networks in the bovine mammary epithelial cells [20]. Therefore, 369 
it has been postulated at least a part of the change in milk fat may be due to the effect of PGT 370 
on milk fat synthesis in mammary glands. 371 
In the present study, the postpartal BCS and BW loss was less as a result of PGT- treatment. 372 
These findings supported those of Smith et al. [25] that showed higher BCS in cows receiving 373 
2.0 or 4.0 mg/kg TZDs for 25 d prepartum. However, Smith et al. [15] and Schoenberg and 374 
Overton [16] did not find any differences in BCS or BW in cows treated prepartum with 375 
TZDs. The lower concentrations of NEFA and BHBA indicated a lower negative energy 376 
balance during the peri- and postpartal periods in PGT-treated cows. Moreover, lesser 377 
amounts of energy used for milk fat synthesis and possibly more energy intake (as DMI) are 378 
possible reasons for less BW and BCS loss during postpartum in PGT-supplemented cows.  379 
The proportion of cows ovulated by d 14 postpatum increased by PGT supplementation (PGT 380 
+/+ and PGT -/+), while the average number of days to ovulation was decreased. Smith et al. 381 
[25] also showed that prepartal administration of 4.0 mg TZDs/kg BW for 25 d decreased the 382 
interval from calving to first ovulation. It has been shown that the NEB adversely influenced 383 
the interval from calving to ovulation [51]; however, reproductive efficiency improved as 384 
BCS loss decreased [52] in dairy cows. In this study, dietary supplementation of PGT 385 
decreased peri- and postpartal NEFA, BHBA and postpartum loss of BCS and BW, and 386 
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caused a decrease in the NEB. In agreement with the results of this study, there are studies 387 
showing that administration of insulin or insulin sensitizing agents during the prepartum 388 
period stimulate ovulation and improve the reproductive performance [49, 53, 54]. In 389 
addition, studies in ruminants and rats [17, 55, 56] showed that PPARγ was widely expressed 390 
in reproductive tissues and ovarian follicles and expression of these receptors increased as 391 
ovulation was approached. This implies a possible direct effect of PGT on specific receptors 392 
leading to a higher proportion of cows ovulating postpartum. However, PGT increased 393 
postpartal concentration of IGF-1 which is considered as a crucial factor for early postpartum 394 
ovulation. In this regard, Kawashima et al [57] demonstrated that ovulation and final 395 
development of the preovulatory follicle is strictly dependent on increasing plasma levels of 396 
IGF-1 and insulin during the first postpartal follicular wave, while low concentration of IGF-397 
1 delays ovulation [58]. Accordingly, PGT may provide a more appropriate metabolic milieu 398 
as well as having a direct effect on the ovulatory process. 399 
The average number of days open was decreased and proportion of pregnant cows during 120 400 
DIM increased in PGT-supplemented cows. Decreased days open is described by shorter 401 
intervals between inseminations and more conception per insemination. Interestingly, PGT 402 
supplementation during both the pre- and postpartal periods (PGT +/+) resulted in 14 d and 403 
19 d decreases in days open compared to PGT (+/-) and PGT (-/+), respectively. This 404 
indicated a synergic interaction between pre- and postpartal supplementation of PGT, and a 405 
relative advantage of supplementing PGT during both the pre- and postpartal periods.  406 
Butler et al. [49] reported that prepartal administration of insulin resulted in earlier postpartal 407 
ovarian activity and improved the reproductive performance. Consistent with the results of 408 
the present study, it has been demonstrated that conception rate was higher in cows that 409 
showed fewer days to first service [59]. The ovarian follicles in the cows supplemented with 410 
PGT during the transition period might experience more appropriate metabolic and hormonal 411 
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conditions, resulting in more competent oocytes. Insulin resistance decreases the quality of 412 
oocytes, leading to a decline in reproductive performance and early embryo development 413 
[60]. Consistent with the results of the present study, supplementation of chromium, an 414 
insulin sensitizing element, reduced plasma concentrations of NEFA and negative energy 415 
balance in heat-stressed animals [61], resulting in improvement of the reproductive 416 
performance in transition dairy cows. Therefore, improved hormonal and metabolic 417 
conditions as a result of PGT supplementation may be involved in the improvement of the 418 
reproductive performance in dairy cows. 419 
4.1. Conclusions 420 
Dietary supplementation of PGT during the transition period decreased peri- and postpartal 421 
plasma NEFA, BHBA, and TG concentrations and also decreased milk fat content, BCS and 422 
BW loss during the postpartal periods in Holstein dairy cows. The improved metabolic health 423 
in PGT-supplemented cows effectively enhanced the postpartum ovulation resumption 424 
activity and reproductive performance. However, better productive and reproductive 425 
performances were observed when PGT was supplemented during both the pre- and 426 
postpartum periods. According to the results of the present study and the previous studies on 427 
the effect of TZDs on transition dairy cows, oral or intravenous administration of these drugs 428 
seems to have beneficial effects on metabolic dynamics and reproduction; however, further 429 
research should be conducted to confirm the mechanisms involved in the effects of PGT and 430 
PPAR-γ on metabolic dynamics, ovulation and reproductive performance in dairy cows. 431 
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Figure caption 602 
Figure 1. An outline of the experimental design indicating initiation of dietary treatment and 603 
duration of pioglitazone (PGT) supplementation. Dairy cows (n=20 cow/treatments) were fed 604 
four experimental diets from d -14 to +21, relative to parturition. PGT was supplemented at 6 605 
mg /kg BW to TMR.  606 
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Table 1. Ingredients and chemical composition (DM basis) of the experimental diets 607 
Ingredients Prepartum diet  Postpartum diet  
Alfalfa hay 26.15  22.00  
Corn silage 31.64  20.33  
Cottonseed,  whole 2.74  7.42  
Soybean, whole- roasted  ---  2.47  
Meat meal  ---  1.28  
Beet pulp   ---  4.08  
Barley grain 12.27  10.48  
Corn grain 9.29  13.83  
Soybean meal 9.07  12.1  
Wheat bran 3.15  1.5  
Corn germ meal  ---  1.05  
Common salt   ---  0.43  
Sodium bicarbonate  ---  0.90  
Dicalcium phosphate  ---  0.3  
Calcium carbonate  0.89  0.8  
Magnesium oxide  ---  0.18  
Bentonite  ---  0.27  
Vitamin and mineral premix1 0.90  0.67  
Ammonium chloride 3.10   --- 
Magnesium sulfate 0.80  --- 
Composition   
DM, % 50 55 
NEL (Mcal/kg DM) 1.53 1.66 
EE, %  3.2 4.6 
CP , %  14.1 17.1 
ADF, %  24.1 22.13 
NDF, %  36.2 32.2 
1. Contained (per kg): 16,000,000 IU vitamin A; 3,200,000 IU vitamin D; 48,000 IU vitamin 608 
E; 24.0 g Mn; 24.0 g Zn; 24.0 g Fe; 12.8 g Cu; 1.44 g I; 0.32 g Se; and 0.32 g Co. 609 
 610 
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 618 
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 620 
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Table 2. Least squares means for the effect of dietary supplementation of pioglitazone (6 mg 622 
PGT/kg BW) on plasma metabolites during transition periods in Holstein cows 623 
(n=10/treatment1) 624 
 625 
  Diets1   
Item  PGT(+/+) PGT(+/-) PGT(-/+) PGT(-/-)  SEM 
NEFA (mmol/L)        
Peripartum2  0.65b 0.72ab 0.82a 0.79a  0.05 
Postpartum3  0.52b 0.59b 0.60b 0.72a  0.05 
BHBA (mmol/L)         
Peripartum  0.56b 0.57ab 0.61ab 0.65a  0.04 
Postpartum  0.56 0.55 0.73 0.63  0.07 
Cholesterol (mg/dL)        
Peripartum  96.13 90.30 88.90 98.90  4.40 
Postpartum  133.52 131.22 134.25 122.58  8.90 
Triglyceride (mg/dL)        
Peripartum  19.99c 23.61b 20.68bc 28.72a  1.30 
Postpartum  18.08b 19.97b 19.37b 24.07a  1.76 
Glucose (mg/dL)        
Peripartum  58.98a 55.38ab 47.86bc 46.83c  2.60 
Postpartum  49.93 52.10 45.76 53.66  3.66 
a–c Values with different superscripts within a row indicate a significant difference, P < 0.05. 626 
1
 Diets consisted of PGT (+/+): supplementation of PGT in pre- and postpartum periods (d -627 
14 to +21 relative to parturition), PGT (+/-): supplementation of PGT only during the 628 
prepartum period (d -14 to parturition), PGT (-/+): supplementation of PGT only during the 629 
postpartum period (d 0 to +21 relative to parturition) and PGT (-/-): no PGT supplementation. 630 
2
 Represents data collected weekly from 7 d before parturition through 7 d postpartum. 631 
3
 Represents data collected weekly from parturition through 21 d postpartum. 632 
 633 
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Table 3. Least squares means for the effect of dietary supplementation of pioglitazone (6 mg 640 
PGT/kg BW) on some plasma hormones during the transition period in Holstein cows 641 
(n=10/treatment) 642 
 643 
  Treatments1   
Item  PGT(+/+) PGT(+/-) PGT(-/+) PGT(-/-)  SEM 
Insulin (µIU/mL)        
Peripartum2  8.68 9.21 8.30 8.11  0.69 
Postpartum3  8.21 9.13 8.18 9.00  0.59 
GH (µg/L)         
Peripartum  3.68 3.98 4.22 4.02  0.31 
Postpartum  2.83 3.19 3.10 3.46  0.40 
IGF-1 (µg/L)        
Peripartum  48.11a 40.06ab 38.92ab 34.03b  4.27 
Postpartum  39.91a 35.03ab 32.67ab 30.55b  3.31 
a–c Values with different superscripts within a row indicate a significant difference, P < 0.05. 644 
1
 Diets consisted of PGT (+/+): supplementation of PGT in pre- and postpartum periods (d -645 
14 to +21 relative to parturition), PGT (+/-): supplementation of PGT only during the 646 
prepartum period (d -14 to parturition), PGT (-/+): supplementation of PGT only during the 647 
postpartum period (d 0 to +21 relative to parturition) and PGT (-/-): no PGT supplementation. 648 
2
 Represents data collected weekly from 7 d before parturition through 7 d postpartum. 649 
3
 Represents data collected weekly from parturition through 21 d postpartum. 650 
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Table 4. Least squares means for the effect of dietary supplementation of pioglitazone (6 mg 662 
PGT/kg BW) on production traits during the postpartum period in Holstein cows 663 
(n=20/treatment) 664 
 Treatments1  
Item PGT (+/+) PGT (+/-) PGT(-/+) PGT (-/-) SEM 
Body weight (kg) 639.15 639.51 637.64 635.87 1.26 
Body weight loss (kg) 30.86c 37.44b 39.16ab 41.60a 0.09 
BCS2 3.34 3.33 3.37 3.25 0.05 
BCS loss 0.54b 0.60b 0.63b 0.77a 0.04 
Milk yield, kg/d 40.92 42.80 42.21 42.97 1.50 
4% FCM3, kg/d 40.06 40.71 41.35 43.53 1.33 
Fat, % 3.91b 3.90b 3.89b 4.15a 0.11 
Fat, kg/d 1.57b 1.60b 1.63ab 1.77a 0.05 
True protein, % 3.16 3.14 3.19 3.27 0.08 
True protein, kg/d 1.27 1.29 1.31 1.39 0.07 
Lactose, % 4.78 4.67 4.71 4.77 0.05 
Lactose, kg/d 1.96 1.97 2.00 2.06 0.08 
Total solids, % 12.12 12.29 12.34 12.40 0.12 
Total solids, kg/d 4.95 5.07 5.17 5.29 0.18 
a,b Values with different superscripts within a row indicate a significant difference, P < 0.05. 665 
1
 Diets consisted of PGT (+/+): supplementation of PGT in pre- and postpartum periods (d -666 
14 to +21 relative to parturition), PGT (+/-): supplementation of PGT only during the 667 
prepartum period (d -14 to parturition), PGT (-/+): supplementation of PGT only during the 668 
postpartum period (d 0 to +21 relative to parturition) and PGT (-/-): no PGT supplementation. 669 
2
 Based on a 5-point scale. 670 
3
 4% FCM = fat-corrected milk, calculated as [0.4 × milk production (kg d−1)] + [15 × fat 671 
yield (kg d−1)]. 672 
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Table 5. Least squares means for the effect of dietary supplementation of pioglitazone (6 mg 681 
PGT/kg BW) on reproductive traits in Holstein cows (n=20/treatment) 682 
 Treatments 1  
Item PGT(+/+) PGT(+/-) PGT(-/+) PGT(-/-) SEM 
First ovulation ≤ 14 d, 
%(n/group) 45%(9/20)
a
 15%(3/20)b 30%(6/20)ab 15%(3/20)b 0.11 
First ovulation ≤ 21 d, % 
(n/group) 65%(13/20) 60%(12/20) 70%(14/20) 45%(9/20) 0.13 
First ovulation (d) 18.37 b 21.00 ab 19.60 b 23.05 a 1.29 
      
Median days to first 
estrus 
40 41 40 45 2.3 
Median days to first 
service 44
b
 50ab 46b 53a 2.8 
First to second 
insemination interval (d) 34
b
 30b 45ab 55a 5 
Median days open 133 b 147b 152b 169 a 7 
  
 
   
Number of services per 
conception 2.56
b
 2.28b 3.00ab 3.80a 0.55 
Pregnant to first 
insemination, %(n/group) 10.5%(2/19) 26%(5/19) 16.5%(3/18) 5.5%(1/18) 0.10 
Pregnant by 120 DIM, % 
(n/group) 53%(10/19)
a
 42% (8/19)a 39% (7/18)a 11% (2/18)b 0.13 
a, b Values with different superscripts within a row indicate a significant difference, P < 0.05. 683 
1
 Treatments included PGT (+/+): supplementation of PGT in pre- and postpartum periods (d 684 
-14 to +21 relative to parturition), PGT (+/-): supplementation of PGT only during the 685 
prepartum period (d -14 to parturition), PGT (-/+): supplementation of PGT only during the 686 
postpartum period (d 0 to +21 relative to parturition) and PGT (-/-): no PGT supplementation. 687 
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Highlights 
 Dietary supplementation of PGT during the transition period decreased peri- and 
postpartal plasma NEFA, BHBA, and TG concentrations and also decreased milk fat 
content, BCS and BW loss during the postpartal periods in dairy cows.  
 PGT had positive effects on postpartum resumption of ovarian activity and increased the 
number of ovulated cows during the postpartum period. 
 The average number of days open was decreased and proportion of pregnant cows during 
120 DIM increased in PGT-supplemented cows. 
 Better productive and reproductive performances were observed when PGT was 
supplemented during both the pre- and postpartum periods 
 
